Aussie joins the US$1 billion club

Telix is predicting revenues of more than a billion US dollars for the calendar year 2026, which would be a 25 per cent increase on 2025.

After releasing its second quarter results Telix said it expects revenue for the year to be at the upper end of the guidance of $1.355-1.384 billion (US$950-970 million), with the addition of $57 million (US$40 million) from a deal with Regeneron.

"We delivered another quarter of growth with US dose volumes increasing seven per cent during the quarter, driven by growing demand for Gozellix and continued strength across our PSMA7 imaging portfolio," Telix MD and CEO, Dr Christian Behrenbruch, said.